GLP‑1 therapy is powerful. But without the right support, most patients will plateau, lose muscle, struggle with side effects, or regain weight when treatment ends. Here’s why SLM+ fills the gap.
GLP‑1 Medications: Game-Changing but Incomplete
(GLP‑1s: Ozempic®, Wegovy®, Saxenda®, Mounjaro®, Zepbound®)
GLP‑1s help patients:
-
Reduce appetite
-
Lower calorie intake
-
Achieve meaningful early weight loss
But they do not:
-
Protect lean muscle mass
-
Maintain metabolic rate
-
Stabilize blood sugar swings
-
Prepare the body for post-therapy transitio
That’s where most patients — and providers — run into problems.
The 4 Gaps in Every GLP‑1 Program
-
Plateaus – Weight loss slows after 3–6 months due to muscle loss and metabolic adaptation.
-
Muscle Loss – Without nutritional or metabolic support, lean mass declines, slowing calorie burn.
-
Side Effects – GI issues, fatigue, and energy swings push patients to quit early.
-
Regain Risk – When the medication stops, the body is less prepared to maintain results.
SLM+: The Bridge GLP‑1 Therapy Needs
SLM+ was formulated to complete the GLP‑1 protocol, filling the exact gaps left by medication:
-
Supports glucose stability → reduces crashes, cravings, and fatigue
-
Protects muscle mass → maintains metabolic burn during calorie restriction
-
Helps manage side effects → smoother digestion and more stable energy
-
Aids post‑therapy transition → reduces risk of rebound weight gain
Why It Should Be Standard in Every GLP‑1 Protocol
Patients deserve more than just early results. They deserve:
-
A plan for the middle (plateau phase)
-
A plan for the end (offboarding without regain)
-
Confidence that their investment in therapy lasts
That’s why SLM+ should be considered an essential adjunct for any patient on GLP‑1 therapy — whether prescribed in a clinic, via telehealth, or managed individually.
The Bottom Line
GLP‑1s work. But without addressing plateaus, muscle loss, side effects, and regain risk, patients are set up for disappointment.
SLM+ is the missing piece that helps transform short‑term results into long‑term success.
👉 Complete your GLP‑1 journey.
Discover how SLM+ fits into every phase of therapy:
Medical Disclaimer:
STAAR LABS is not a licensed pharmacy, medical provider, or drug manufacturer. The information provided is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. SLM+ is a dietary supplement and is not intended to replace prescription medications or medical advice. Patients should consult their licensed healthcare provider before making any changes to their medical treatment, diet, or supplement use.
Trademark Disclaimer:
Ozempic®, Wegovy®, and Saxenda® are registered trademarks of Novo Nordisk A/S.
Mounjaro® and Zepbound® are registered trademarks of Eli Lilly and Company.
STAAR LABS is not affiliated with, sponsored by, or endorsed by Novo Nordisk A/S or Eli Lilly and Company. References to these products are for informational purposes only to describe commonly prescribed GLP-1 therapies.
Research & Innovation Disclosure:
STAAR LABS collaborates with clinics, pharmacies, and healthcare professionals to advance innovation in real-world metabolic health protocols. We welcome research partners committed to improving outcomes through evidence-based nutraceutical and pharmaceutical strategies.
